Ozempic face: why your face changes and what you can do about it

Medically reviewed by Dr. Jaramillo, a doctor at Goodweigh. Last updated on 7 October 2026
Short answer from Dr. Jaramillo
‘Ozempic face’ is a collective term for a hollow-looking face following significant weight loss. It is not a recognised side effect, but a well-known consequence of significant weight loss, even without medication. Facial volume loss does not reverse naturally because subcutaneous fat pads do not spontaneously regenerate post-weight loss. You can minimise it by not losing weight too quickly, maintaining good nutrition and hydration (adequate protein intake) can help skin elasticity, but true volume recovery requires medical/dermatological management.
Dr. Jaramillo, doctor at Goodweigh
Want to find out more? Start your intake here
Many people who lose weight with GLP-1 medication notice that their face changes. Their cheeks become more hollow and their skin feels looser. Online, this is known as the ‘Ozempic face’. You can read about what it is, what causes it, what you can do about it and whether it goes away.
What exactly is Ozempic face?
‘Ozempic face’ is not a medical diagnosis, but a popular term for facial changes following significant weight loss. These include sunken cheeks, deeper creases on either side of the nose and sagging skin.
The term originated on social media, not from clinical research. ‘Ozempic face’ is not a recognised side effect of Wegovy, Mounjaro or Saxenda. However, a literature review on skin quality does describe facial volume loss, thinner skin and reduced levels of collagen and elastin in users of GLP-1 agents. The evidence comes from studies of varying designs, including individual patient case reports.
What causes a hollow-looking face with GLP-1 medicines?
A hollow-looking face is caused by the fact that you also lose fat in your face and your skin does not always shrink at the same rate. With Wegovy, Mounjaro and Saxenda, the weight lost consists mainly of fat.
A retrospective study using CT and MRI scans examined twenty patients before and after treatment with a GLP-1 agonist. The volume in the midface decreased on average, and the superficial volume decreased more markedly the more weight a person lost. For every 10 kilograms lost, this amounted to approximately 7 per cent less volume in the midface. The study was small and had no control group, so this is an indication rather than a proven risk.
This is not unique to GLP-1 medication. Excess skin is also common after stomach reduction surgery (bariatric surgery), according to the Dutch NHG guideline on obesity. This applies to the face as well: after a great deal of weight loss, sagging tissue and less elastic skin on the face and neck can make you look older.
Does muscle loss also play a part in Ozempic face?
When you lose weight, you lose not only fat but also some fat-free mass. This is not the same as muscle: it also includes organs, bone and fluid, as explained in a review on fat-free mass in relation to GLP-1 agents.
In that review, the proportion of fat-free mass in the weight lost varies considerably between studies. A meta-analysis of 20 studies showed that this proportion is roughly the same for GLP-1 agonists and for weight loss achieved through lifestyle changes. Loss of lean body mass is therefore generally associated with significant weight loss, with or without medication. The evidence shows that weight loss with GLP-1 medication leads to depletion of facial fat pads rather than changes to the facial muscles.
Does this apply to all GLP-1 medicines?
Yes, it’s mainly about the amount of weight you lose, rather than any one particular treatment. This applies to semaglutide (Ozempic, Wegovy and Rybelsus), tirzepatide (Mounjaro) and liraglutide (Saxenda).
For all three, the weight lost consists mainly of fat, as stated in the package leaflets for Wegovy, Mounjaro and Saxenda. In the meta-analysis, the proportion of fat-free mass was slightly higher with semaglutide than with tirzepatide and liraglutide. There is no evidence that one drug alters facial appearance more than another. You can read more about these medicines under Ozempic, Wegovy, Mounjaro, Saxenda and Rybelsus.
Where on your face do you see Ozempic face most?
The face changes most noticeably in areas where fat and skin determine its volume, such as the cheeks. People also mention the jawline and the area around the eyes. Too little is known about changes to the nose and eyes to comment on them.
The review on skin quality shows that the changes are not limited to the cheeks: the skin itself also becomes thinner and less elastic. The extent to which this affects you varies from person to person.
How can you minimise Ozempic face?
The most important thing is to lose weight gradually: a review cites rapid weight loss as a risk factor for more pronounced skin changes. The dose of GLP-1 medication is increased gradually to minimise gastrointestinal side effects. Our doctors also use this gradual increase to prevent you from losing weight too quickly.
Strength training helps to maintain muscle mass. A review on strength training in conjunction with incretin-based medicines states that supervised training can promote muscle growth in people in general. In that review, insufficient protein intake is also identified as a risk factor, but it has not been demonstrated whether protein or exercise protects the face against volume loss. Tips on protein-rich diets for weight loss and the best sports for weight loss will help you get started. Also read what to eat whilst taking GLP-1 medication.
Also, make sure you drink enough, as this is important when taking Wegovy to prevent dehydration. The review does not specifically evaluate retinoids or sunscreen, but it does recommend early dermatological intervention and hydration to support the skin during GLP-1 treatment.
Can Ozempic face be reversed?
Not on its own. Facial volume loss does not reverse naturally because subcutaneous fat pads do not spontaneously regenerate post-weight loss. True volume recovery requires medical or dermatological management. If you have any concerns about your face, discuss with your doctor what is right for you.
Regaining weight is not a solution. You should therefore also read about what happens when you stop taking Ozempic. Some people opt for cosmetic procedures such as fillers. This is a personal choice that you should discuss with a doctor or specialist, and is not part of our treatment.
Is Ozempic face dangerous, and when should you see your doctor?
A hollow face is primarily an aesthetic issue and not a dangerous side effect. However, do contact your doctor if you lose weight very quickly, are barely eating or start to experience any symptoms.
Hair loss is another visible change. Hair loss was reported more frequently with Wegovy than with a placebo, particularly in cases of significant weight loss. Hair loss is also listed in the patient information leaflet for Mounjaro. Discuss how quickly you are losing weight with your doctor or coach. You can read about how the programme works under How it works.
Ozempic face in perspective
A hollow-looking face can occur following significant weight loss, with or without medication. It is not a dangerous side effect. You may be able to minimise the risk by losing weight gradually, eating and drinking well, and discussing your pace with your healthcare professional. If you’d like to know how much weight you can expect to lose on average, read about how much weight you lose with Ozempic or how many kilos you lose per month.
Frequently Asked Questions
Is ‘Ozempic face’ an official side effect?
No. ‘Ozempic face’ is not a recognised side effect. It is a collective term for facial changes that may be associated with significant weight loss.
Can I prevent Ozempic face?
You can limit it, but not eliminate it entirely. It is recommended that you lose weight gradually, eat and drink well, and discuss the pace with your doctor. Our doctors also use a gradual increase in dosage to prevent losing weight too quickly.
Will a hollow face return to how it was?
No, not on its own. Facial volume loss does not reverse naturally because subcutaneous fat pads do not spontaneously regenerate after weight loss. True volume recovery requires medical or dermatological management. Discuss this with your doctor if it is a cause for concern.
Will I also get the Ozempic face with Wegovy, Mounjaro or Saxenda?
Yes, that’s possible. It mainly depends on how much weight you lose, not on any one particular medicine.
What should I do if my face changes?
Discuss this with your doctor or coach, especially if you are losing weight rapidly.
Frequently asked questions about Ozempic face
No, "Ozempic face" is not a recognized medical term or an approved side effect listed in the patient information leaflet. It is a popular term used to describe the visible loss of facial volume that can occur with rapid and significant weight loss, regardless of the medication used.
The risk is associated with the amount and speed of weight loss, rather than the specific medication. Because tirzepatide in Mounjaro typically results in slightly more weight loss on average than semaglutide, the effect on facial volume could theoretically be slightly more pronounced at a similar rate of weight loss.
Yes, a gradual rate of weight loss is the most important way to minimize risk. The standard titration schedule for GLP-1 medication is already designed with this in mind, and coaching can help you further monitor your progress.
Facial volume may partially return once your weight stabilizes, as the body gradually builds up some fat again. However, skin elasticity recovers more slowly, which means slight sagging can sometimes remain visible for longer.
Dermal fillers are an existing cosmetic option that some people consider, but this is a personal choice independent of your GLP-1 treatment. Goodweigh does not recommend this, nor do we offer it as a service; please discuss this with a qualified specialist if you are interested.
- Sharma, R. K., Vittetoe, K. L., Barna, A. J., Takkouche, S., Varelas, A. N., Yang, S. F., Stephan, S. J., & Patel, P. N. (2025). Radiographic midfacial volume changes in patients on GLP-1 agonists. Otolaryngology-Head and Neck Surgery, 173(2), 360-366. https://pubmed.ncbi.nlm.nih.gov/40407186/
- Neeland, I. J., Linge, J., & Birkenfeld, A. L. (2024). Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes, Obesity and Metabolism, 26(Suppl 4), 16-27. https://pubmed.ncbi.nlm.nih.gov/38937282/
- Eisa, N., & Barood, O. (2026). Lean mass changes with incretin therapy versus lifestyle intervention: A systematic review and meta-analysis of randomised controlled trials. Diabetes, Obesity and Metabolism, 28(6), 4818-4827. https://pubmed.ncbi.nlm.nih.gov/41877354/
- Locatelli, J. C., Costa, J. G., Haynes, A., Naylor, L. H., Fegan, P. G., Yeap, B. B., & Green, D. J. (2024). Incretin-based weight loss pharmacotherapy: Can resistance exercise optimize changes in body composition? Diabetes Care, 47(10), 1718-1730. https://pubmed.ncbi.nlm.nih.gov/38687506/
- Barone, M., Brunetti, B., D'Emilio, R., Caputo, M. G., Tenna, S., & Persichetti, P. (2026). Effects of GLP-1 receptor agonists on skin quality: A comprehensive literature review. Aesthetic Plastic Surgery, 50(13), 5403-5407. https://pubmed.ncbi.nlm.nih.gov/42162206/
- Waltzman, J. T., Zins, J. E., & Couto, R. A. (2019). Face and neck lifting after weight loss. Clinics in Plastic Surgery, 46(1), 105-114. https://pubmed.ncbi.nlm.nih.gov/30447822/
- European Medicines Agency. Wegovy: productinformatie. https://www.ema.europa.eu/nl/documents/product-information/wegovy-epar-product-information_nl.pdf
- European Medicines Agency. Mounjaro: productinformatie. https://www.ema.europa.eu/nl/documents/product-information/mounjaro-epar-product-information_nl.pdf
- European Medicines Agency. Saxenda: productinformatie. https://www.ema.europa.eu/nl/documents/product-information/saxenda-epar-product-information_nl.pdf




